Nathan Pliam
Venture Partner @ Bay City Capital
San Francisco, United States
Nathan Pliam is a seed investor at Bay City Capital in San Francisco focused on Health Care and Biotechnology. Nathan Pliam is the Founder of Ancora Heart. He previously worked at Bay City Capital LLC as a Venture Partner. Nathan Pliam attended Stanford University School of Medicine.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Nathan Pliam invests in
Stages Nathan Pliam invests in
Countries Nathan Pliam invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (25%)
- Biotechnology 1 (25%)
- Pharmaceutical 1 (25%)
- Health Diagnostics 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
- Series C 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | Series C / Mar 07, 2013 | ||
| Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | Series B / Jul 19, 2011 | ||
| Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | $21.8M / Series A / Sep 10, 2008 | ||
| Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. | $5.5M / Seed / Dec 04, 2006 |
Co-Investors
About Bay City Capital
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.
Bay City Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Beier
Managing Director
|
|||
Fred Gage
Scientific Advisory Board
|
|||
Fred Craves
Managing Director
|
|||
Judy Koh
Managing Director/Chief Financial Officer
|
|||
Lionel Carnot
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Nathan Pliam invest in?
Nathan Pliam invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nathan Pliam?
Public channels for Nathan Pliam include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nathan Pliam last invest?
The most recent investment recorded for Nathan Pliam closed in Mar 2013. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
